

Clinical Policy Title:	ALK Inhibitors
Policy Number:	RxA.917
Drug(s) Applied:	Alecensa, Alunbrig, Lorbrena, Zykadia and Ensacove
Original Policy Date:	12/11/2025
Last Review Date:	12/11/2025
Line of Business Policy Applies to:	All lines of business (except Medicare)

Criteria

I. Initial Approval Criteria

A. Non-Small Cell Lung Cancer (must meet all):

1. Diagnosis of recurrent or metastatic NSCLC;
2. Disease is anaplastic lymphoma kinase (ALK) positive tumor;
3. If the request is for Ensacove, patient has had disease progression on, contraindication or intolerance to, or is not a candidate to one of the following:
 - a. Alecensa (alectinib);
 - b. Alunbrig (brugatinib).

Approval duration

All Lines of Business (except Medicare): 12 months

II. Continued Therapy Approval

A. Non-Small Cell Lung Cancer (must meet all):

1. Auto-approval based on lookback functionality within the past 120 days as a proxy for member responding positively to therapy.

Approval duration

All Lines of Business (except Medicare): 12 months

References

1. Highlights of prescribing information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf
2. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer Version 2.2026. Available at:
https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

Review/Revision History	Review/Revised Date	P&T Approval Date
Policy established.	12/11/2025	12/11/2025

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.